Daratumumab and hyaluronidase-fihj (Subcutaneous)

Medically reviewed by Drugs.com. Last updated on Apr 19, 2022.

Commonly used brand name(s)

In the U.S.

• Darzalex Faspro

Available Dosage Forms:

• Solution

Therapeutic Class: Antineoplastic Agent

Pharmacologic Class: Monoclonal Antibody

Uses for daratumumab and hyaluronidase-fihj

Daratumumab and hyaluronidase-fihj combination injection is used together with bortezomib, melphalan, and prednisone to treat newly diagnosed multiple myeloma (a type of bone marrow cancer) in patients who cannot receive autologous stem cell transplant (transplant that uses their own stem cells).

Daratumumab and hyaluronidase-fihj combination injection is used together with lenalidomide and dexamethasone to treat newly diagnosed multiple myeloma in patients who cannot receive autologous stem cell transplant. It is also used together with lenalidomide and dexamethasone to treat relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma in patients who have received at least 1 previous treatment.

Daratumumab and hyaluronidase-fihj combination injection is used together with bortezomib, thalidomide, and dexamethasone to treat newly diagnosed multiple myeloma who can receive autologous stem cell transplant.

Daratumumab and hyaluronidase-fihj combination injection is used together with bortezomib and dexamethasone to treat multiple myeloma in patients who have received at least 1 previous treatment.

Daratumumab and hyaluronidase-fihj combination injection is used together with pomalidomide and dexamethasone to treat multiple myeloma in patients who have received at least 1 previous treatment (eg, lenalidomide and a proteasome inhibitor).

Daratumumab and hyaluronidase-fihj combination injection is also used together with carfilzomib and dexamethasone to treat relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma in patients who have received 1 to 3 previous treatment.

Daratumumab and hyaluronidase-fihj combination injection is also used alone to treat multiple myeloma in patients who have received at least 3 previous treatments or in patients who did not respond to previous treatments. These previous treatments include a proteasome inhibitor and an immunomodulatory agent.

Daratumumab and hyaluronidase-fihj combination injection is also used together with bortezomib, cyclophosphamide, and dexamethasone to treat newly diagnosed light chain amyloidosis.

Daratumumab and hyaluronidase-fihj is to be given only by or under the supervision of your doctor.

Before using daratumumab and hyaluronidase-fihj

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For daratumumab and hyaluronidase-fihj, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to daratumumab and hyaluronidase-fihj or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of ...